XTalks

DECEMBER 14, 2022

Developed by MIT researchers Jonathan Gootenberg and Omar Abudayyeh, PASTE (Programmable Addition via Site-specific Targeting Elements) gene editing technology can insert genes as long as 36,000 DNA base pairs to liver cells in mice as well as several types of human cells.

Gene Editing 84

Gene Editing DNA Gene Gene Sequencing 84

The Pharma Data

DECEMBER 28, 2020

About Fulgent Genetics. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. TEMPLE CITY, Calif.,

Genetics 52

Genetics Sales Gene Sequencing Marketing 52

FDA Law Blog

OCTOBER 24, 2024

Rather, developers of diagnostic tests and, indeed of any product that relies on free access to gene sequence and other biomarker information, should pay also close attention, as PERA would overturn longstanding judicial precedent. The concerns raised by PERA are not limited to these industries, however.

Gene 62

Gene DNA Genetics Gene Sequencing 62

pharmaphorum

JUNE 23, 2022

Systemic administration of gene-editing drugs would avoid that process with an “off-the-shelf” option for a one-shot, potentially curative treatment for diseases associated with genetic mutations.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

pharmaphorum

FEBRUARY 23, 2022

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The deal is mostly back-loaded, with “double-digit million” dollars in upfront payment, research funding and milestone payments.

Gene Therapy 105

Gene Therapy Gene Gene Sequencing Immune Response 105

pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. market and will wind down in Europe.

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

pharmaphorum

AUGUST 10, 2021

The three-year project – led by respiratory medicine expert Dr Timothy Hinks from the Oxford University Respiratory Medicine Unit – will use whole-genome sequencing of around 500 patients with severe asthma, comparing their gene sequences with control subjects who don’t have asthma. Dr Timothy Hinks.

Gene Sequencing 116

Gene Sequencing Gene Bioinformatics Genome 116

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

pharmaphorum

AUGUST 21, 2020

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. Longwall Ventures and Agilent have both returned to invest in the Series A, which on this occasion was led by BlueYard Capital.

DNA 59

DNA Gene Sequencing Genetics FDA Approval 59

pharmaphorum

SEPTEMBER 14, 2022

Meanwhile, a third gene therapy candidate – SPVN30, which combines the gene sequences in SPVN06 and SPVN20 – is in early development for RP. The post SparingVision raises €75m for eye disease gene therapies appeared first on.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Editing 52

Roots Analysis

OCTOBER 16, 2023

DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence. This has enabled several researchers to study genetic disorders more precisely and closely.

DNA 40

DNA Gene Protein In-Vitro 40

pharmaphorum

FEBRUARY 22, 2021

If a causal link is shown, it could have “significant ramifications” on the use of lentiviral vectors, a type of self-inactivating virus that underpins both approved cell therapies like Novartis’ CAR-T Kymriah as well as a host of experimental therapies that involve genetic manipulation of cells. million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

Pharmaceutical Technology

MAY 26, 2023

As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA.

DNA 130

DNA Manufacturing Gene Gene Therapy 130